↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

AngioDynamics: Sound ship (one warning sign)Sound ship

Angiodynamics $ANGO

Grew revenue 9.5% in FY2026 to $320 million, operating margin -12.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 63.9% of assets.

Last filing8-K · Item 5.02 Departure or Election of Directors; Appointment of Officers, 18 Nov 2026

Next year, 80%$279M–$380M
Growth, on the year9.5%
Operating margin−12.5%
Equity of assets63.9%
Credibility57%
Track record12 of 13
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up AngioDynamics, Inc. ($ANGO). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-11-18. 9 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $320.2M (FY2026). Experience: revenue up 9.5% on the year, up 0.3% a year over 4 years; operating margin -12.5%, up from -13.7%. Soundness: equity 63.9% of assets, return on equity -21.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $279.0M and $380.4M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $258.0M to $412.7M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -12.5% against a 1.2% median; growth 9.5% against 11.6%.

Read from its own SEC filings · nothing written, nothing inferred

AngioDynamics, Inc. against its own record and its peers
Operating marginPeer median 1.2%-12.5%Revenue, on the yearPeer median 11.6%9.5%Equity of assetsPeer median 52.9%63.9%Return on equityPeer median -2.3%-21.5%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus

Speed and cash · fiscal 2025

Cash Compass🌊 In between · no clear cash pattern yet
Inside viewTurns 1.0% of revenue into operating cash; revenue shrinking 1.9% a year over three years; no common dividend.
Outside viewAmong $100M-1B companies: 27th percentile for cash, 28th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)$3M · −$6M · $1M · $1M
Investment book (cash · short · long)$54M · — · — · current ratio 2.19
Revenue swing · equity of assets9.3% · 65.4%

AngioDynamics is growing slower than its size class, with steadier revenue. Its own audited SEC figures.

The figures, as filed

Fiscal year end2026-05-31
Revenue$320M
Revenue, on the year9.5%
Revenue, a year over the record0.3%
Operating margin−12.5%
Operating margin, prior year−13.7%
Net margin−11.5%
Research and development$29M · 9.2% of revenue
Total debt—
Equity of assets63.9%
Return on equity−21.5%
Payout of profit—
Dividend per share—
Earnings per share$-0.88
Book value per share$4.11
Revenue per share$7.71
Shares outstanding41,525,697
Audited years read5

Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.

Classic signals · fiscal 2026Altman Z″ -2.65 distress zone 1968Piotroski F 5 of 9 middling 2000Beneish M -3.08 below the −1.78 line 1999Sloan accruals -14.6% earnings backed by cash 1996DuPont ROE -20.8% = margin -11.5% × turns 1.17 × leverage 1.55

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborAngioDynamics sails as Sound ship1 warning sign

Health watch · 12 monthsDirector or officer change ×3

Versus peersoperating margin −12.5% vs a 1.2% median · revenue growth 9.5% vs 11.6% · cash beats 27% of its size class · growth beats 28% 60 surgical & medical instruments & apparatus filers

Trend · last year to this▲operating margin −13.7% → −12.5% · ▲revenue $292.5M → $320.2M · 5-year revenue: $316.2M · $338.8M · $303.9M · $292.5M · $320.2M

See all 71 surgical & medical instruments & apparatus companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipLemaitre VascularLMATNew ship27.2%13.5%$249.6M
2New shipDexcomDXCMNew ship19.6%15.6%$4.7B
3New shipStrykerSYKNew ship19.5%11.2%$25.1B
4New shipMedlineMDLNNew ship7.8%11.5%$28.4B
5Sound shipResMedRMDSound ship33.4%9.9%$5.7B
6Sound shipWest Pharmaceutical ServicesWSTSound ship19.0%6.3%$3.1B
7Sound ship3M CompanyMMMSound ship18.6%1.5%$24.9B
8Sound shipBoston ScientificBSXSound ship18.0%19.9%$20.1B
9Sound shipInsuletPODDSound ship17.5%30.7%$2.7B
10Sound shipInterpace BiosciencesIDXGSound ship10.5%−17.5%$38.7M
11Sound shipInfusystem HoldingsINFUSound ship8.3%6.4%$143.4M
12Sound shipNephrosNEPHSound ship6.1%32.7%$18.8M
13Sound shipAngioDynamicsANGO · this companySound ship−12.5%9.5%$320.2M
14Sound shipBluejay DiagnosticsBJDXSound ship−3741.5%—$0.2M
15Sound shipModular MedicalMODDSound ship——$0.0M
16Weathered boatMicrobot MedicalMBOTWeathered boat782.8%−88.5%$0.1M
17Weathered boatPro-DexPDEXWeathered boat16.8%16.5%$77.5M
18Weathered boatSanuwave HealthSNWVWeathered boat11.2%35.0%$44.1M
19Weathered boatMiniMed GroupMMEDWeathered boat−6.1%14.3%$3.1B
20Weathered boatiRhythm HoldingsIRTCWeathered boat−7.7%26.2%$747.1M
21Weathered boatSI-Bone, Inc.SIBNWeathered boat−11.1%20.2%$200.9M
22Weathered boatNovoCure LimitedNVCRWeathered boat−23.5%8.3%$655.4M
23Weathered boatIntegra Lifesciences HoldingsIARTWeathered boat−30.2%1.5%$1.6B
24Weathered boatProcept BioRoboticsPRCTWeathered boat−33.7%37.2%$308.1M
25Weathered boatBeta BionicsBBNXWeathered boat−71.5%53.9%$100.3M
26Weathered boatenVVeno MedicalNVNOWeathered boat−24566.5%−83.3%$0.0M
27Weathered boatAutonomix MedicalAMIXWeathered boat——$0.0M
28Weathered boatOdyssey HealthODYYWeathered boat——$0.0M
29Old boatGlucotrackGCTKOld boat1685.6%378.3%$0.2M
30Old boatTeleflex IncorporatedTFXOld boat5.9%17.2%$2.0B
31Old boatAccuray IncorporatedARAYOld boat−6.6%−12.3%$401.9M
32Old boatSkinHealth SystemsSKINOld boat−6.9%−10.0%$300.8M
33Old boatSonoma PharmaceuticalsSNOAOld boat−12.6%36.7%$19.5M
34Old boatCarlsmedCARLOld boat−60.5%85.9%$50.5M
35Old boatCVRxCVRXOld boat−90.5%10.4%$56.7M
36Old boatOrchestra BioMed HoldingsOBIOOld boat−154.7%1169.2%$33.5M
37Old boatProfound MedicalPROFOld boat−256.3%50.7%$16.1M
38Old boatIntelligent Bio SolutionsINBSOld boat−299.1%38.1%$4.2M
39Old boatTenon MedicalTNONOld boat−324.3%20.4%$3.9M
40Old boatBeyond AirXAIROld boat−378.2%107.3%$7.7M
41Old boatInspireMDNSPROld boat−552.6%28.1%$9.0M
42Old boatFemasysFEMYOld boat−767.0%40.8%$2.3M
43Old boatHarvard Apparatus Regenerative TechnologyHRGNOld boat−982.2%63.7%$0.7M
44Old boatSeaStar Medical HoldingICUOld boat−986.6%814.1%$1.2M
45Old boatLucid DiagnosticsLUCDOld boat−1054.8%8.3%$4.7M
46Old boatProfusaPFSAOld boat−4500.0%—$0.1M
47Old boatVivosRDGLOld boat−4628.7%144.3%$0.1M
48Old boatCO-DiagnosticsCODXOld boat−8058.8%−84.1%$0.6M
49Old boatPulse BiosciencesPLSEOld boat−21982.6%—$0.3M
50Old boatPAVmedPAVMOld boat−30712.7%−97.6%$0.1M
51Old boatStimCell EnergeticsSTMEOld boat—−100.0%$0.0M
52Old boatFractyl HealthGUTSOld boat—−100.0%$0.0M
53Old boatGlobal Innovative PlatformsGIPLOld boat——$0.0M
54Old boatAdagio Medical Holdings, Inc.ADGMOld boat—−100.0%$0.0M
55Rotting at the dockBiotricityBTCYRotting at the dock10.6%16.0%$16.0M
56Rotting at the dockPremier Air Charter HoldingsPREMRotting at the dock−8.5%53.6%$31.9M
57Rotting at the dockSS Innovations InternationalSSIIRotting at the dock−19.3%105.7%$42.5M
58Rotting at the dockNeuroneticsSTIMRotting at the dock−21.1%99.2%$149.2M
59Rotting at the dockNexGelNXGLRotting at the dock−29.3%31.5%$11.4M
60Rotting at the dockCytosorbentsCTSORotting at the dock−39.8%4.1%$37.1M
61Rotting at the dockTela BioTELARotting at the dock−42.0%15.8%$80.3M
62Rotting at the dockSpectral AIMDAIRotting at the dock−43.8%−33.6%$19.6M
63Rotting at the dockNuo TherapeuticsAURXRotting at the dock−76.0%142.7%$3.3M
64Rotting at the dockInvo FertilityIVFRotting at the dock−105.8%4.3%$6.8M
65Rotting at the dockVivos TherapeuticsVVOSRotting at the dock−114.1%16.0%$17.4M
66Rotting at the dockDarioHealthDRIORotting at the dock−163.9%−17.3%$22.4M
67Rotting at the dockPicard MedicalPMIRotting at the dock−268.4%12.5%$4.9M
68Rotting at the dockOsr HealthOSRHRotting at the dock−631.0%−17.7%$2.9M
69Rotting at the dockPetVivo HoldingsPETVRotting at the dock−793.9%0.8%$1.1M
70Rotting at the dockSintx TechnologiesSINTRotting at the dock−1053.1%−64.7%$1.0M
71Rotting at the dockFlyte AviationVJETRotting at the dock−2581.6%95.0%$0.8M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Sailing speed follows growth: -1.9% a year crosses the harbor in 86 seconds.

🌊 Visit the Bay →
The warning signs
  • Operating loss a margin of -12.5% in FY2026

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Brand success factors · calendar 2025

The Trillion Score: 443

Exponential Success Score

Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.

How The Trillion Score works. We read eight measures of success from Angiodynamics's own SEC filings and test each one against the public companies in its field, here surgical & medical instruments & apparatus. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.

What it says here. At 443, Angiodynamics's odds of thriving come to 28%, against about 37% for the typical filer. It meets 1 of 8 success points.

443The Trillion Score
28%modeled odds of thriving over three years
HighFall Risk
#86 of 116rank in its field
#2,201 of 2,824rank across all filers

What the score means

The higher the score, the more often companies went on to thrive. At this level, about 31 of every 100 did.

31%Under 450This company: 44335%450 to 49938%500 to 54944%550 to 59957%600 and up

Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.

Fall Risk: High

Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 41 of every 100 companies in the High band did. That is the group's history, not a forecast for this company.

MoneyIt keeps about 0 cents of free cash from each sales dollar after paying for its plants and equipment.cash negative over five years
SwingsIn its worst fifth of years, sales fell about 11% a year.-10.9% a year
Filed eventsIn the last two years it told the SEC about 4 filings on leadership or auditor changes.4

The eight success points

PointWhat it meansPlace in field
SpeedSales grew slower than much of its field.15 of 100Not yet
SteadinessGrowth swung a lot for what it delivered.26 of 100Not yet
Price premiumIt keeps less of each sales dollar than the leaders in its field.38 of 100Not yet
Margin stays above the fieldIts margin has not held above the field for long.22 of 100Not yet
Moat half-lifeIts margin edge is fading fast, or it has none yet.33 of 100Not yet
Brand spend yieldBrand spending returns more gross profit than for most of its field.94 of 100Met
Learning curveCosts have not fallen much as a share of sales as it grew.30 of 100Not yet
Climb in the fieldIt has not been moving up the size ranks in its field.35 of 100Not yet

Price premium -$19M is the extra gross profit over a field-median margin. Momentum -$19M is gross profit times growth above the field's pace.

The actuarial view

CredibilityWith 8 years of filings, the record earns 70% of the weight. The rest stays at the middle of the field.0.70
Severe decline, class DAbout 34 of every 100 companies with this many points fell 30% or stopped reporting within three years.34.3%
Actual vs expectedSales are 28% lower than if it had simply kept pace with its field.0.72

Top of its field: #1 SANUWAVE Health · #2 AVITA Medical · #3 TELA Bio · #4 Inspire Medical Systems · #5 Insulet

Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.